18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy (IMMUNOPET)

Regional University Hospital Center (CHRU)

Status: Completed

Conditions: Melanoma; 18F-FDG; Immunotherapy; Positron-Emission Tomography; NSCLC

Study type: Observational

Funder types: Other

Identifiers

NCT03741231

IMMUNOPET ( 29BRC17.0253).

Details and patient eligibility

About

Study the EFS and OS according to 18FDG PET in patients with melanoma or non small cell lung cancer treated by immunotherapy.

Full description

Study EFS in patients with melanoma or NSCLC treated by immunotherapy (anti CTLA4 or anti PDL1) and performed18FDG PET

Multicentric retrospective study

Enrollment: 70 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients treated for melanoma or NSCLC with immunotherapy (anti CTLA4 or antiPDL1)
• patients treated in Brest, Morlaix, Landerneau hospital
• patients performed FDG PET
• no opposition to study

Exclusion criteria

• age under 18 years old
• refusal to participate